Skip to Main Content

Entrepreneurs in Residence

Michael Beaubaire received his undergraduate degree from the University of Pennsylvania's Wharton School of Business and his Medical Doctorate degree from Northwestern University. After a number of years in clinical and hospital practice at McGaw Northwestern Medical Center and Advocate Healthcare, Dr. Beaubaire shifted gears into the financial sector and worked at Salomon Bros, Lincoln Park Capital and HCA Capital Partners. He is currently a board member and advisor to a number of biotech companies. Michael currently helps Helix 51 companies with partnering and fundraising activities from investors and bioscience companies.

Tom Cox, JD brings a unique perspective to his practice, which focuses on serving the needs of privately held businesses, their executives, and their investors. In particular, he works closely with emerging and growth-oriented businesses in initial organizational, structural, and shareholder activities and board matters, equity incentive plan development and implementation, general corporate, commercial, and real estate activities, supplier relationships, and general regulatory compliance matters, particularly in the healthcare industry. He regularly supports the legal and business needs of both early stage and middle market firms in connection with equity and debt financings, joint ventures, mergers, acquisitions, and divestitures. Representative clients range from start-ups licensing novel technologies from universities to multi-national, private equity-backed businesses.

Robin Geller, PhD has over 25 years of corporate and academic experience. Her business experience includes extensive work in pharmacovigilance, regulatory strategy, and regulatory intelligence. She has held a number of positions at Baxter in the R&D, Quality, Regulatory and Pharmacovigilance organizations including Director of Pharmacovigilance Intelligence and Safety Writing. Her research expertise is in cell biology, genetics, and immunology. She has led research teams in T cell signaling and tumor vaccine development.

Edwin Moore, PhD brings 40 years of biopharmaceutical, pharmaceutical, and clinical diagnostic industry experience from global companies, Baxter Healthcare Corp, and Abbott Laboratories, in R&D product development. During his career, he has held various roles in CMC pre-clinical product development for recombinant therapeutic proteins and for IV parenteral small molecule products in Analytical Method Development, Stability Testing, Formulation, as well as leading overall pre-clinical product development for a recombinant therapeutic protein product. He has held positions from bench scientist, R&D Product Development, to Sr. Director, Global Analytical Method Development and Validation.

J. Peter Paredes, JD has over 16 years of experience in all aspects of patent prosecution, litigation, licensing, and counseling. Peter developed patent portfolios for clients resulting in five acquisitions or licensing arrangements for over $150 million. Peter works with startups, universities, and investment firms to provide strategic intellectual property acquisition, licensing, and enforcement.

Stephen Simes is an accomplished public company CEO who led a number of biopharmaceutical companies during his over 40 year career in the industry. He has extensive experience developing and implementing corporate strategies, establishing growth metrics, driving performance, and meeting growth objectives through organic expansion, acquisitions, and partnerships. When CEO at RestorGenex Corporation, Mr. Simes built a successful senior executive leadership team and product development portfolio. He also negotiated the merger of RestorGenex with Diffusion Pharmaceuticals, creating a late-stage oncology-focused biotech company. As CEO at BioSante Pharmaceuticals, Inc., Mr. Simes helped secure significant funding through various financing transactions, acquisitions, and license arrangements. BioSante was later acquired by ANI Pharmaceuticals Inc. At Unimed Pharmaceuticals, Inc., a subsidiary of AbbVie Inc., Mr. Simes built, developed, and successfully led research and development, finance, sales, and commercial activities, significantly expanding the product portfolio and increasing stockholder value.